| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| May 11, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Drape Eric51 | Executive VP Global Operations | Sell | 19,804 | $10.22 | $202,412.72 | -21.3% | -2.0% | -28.0% | |
| May 11, 2021 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 150,000 | $22.09 | $3,313,339.27 | -8.4% | +27.9% | +18.2% | |
| May 11, 2021 | ELAN Elanco Animal Health Inc | Garcia Art A45 | Director | Buy | 1,525 | $32.88 | $50,142.00 | +10.2% | -8.2% | -35.6% | |
| May 11, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Fridriksdottir Hafrun47 | Executive VP, Global R&D | Sell | 19,066 | $10.22 | $194,829.73 | -17.1% | -2.0% | -28.0% | |
| May 11, 2021 | BCRX Biocryst Pharmaceuticals Inc | Barnes Alane P70 | Chief Legal Officer | Sell | 102,780 | $12.04 | $1,237,471.20 | -48.2% | +45.4% | -34.6% | |
| May 11, 2021 | AMPH Amphastar Pharmaceuticals, Inc. | Prins Richard K61 | Director | Sell | 15,827 | $18.90 | $299,109.72 | -28.8% | +5.8% | +73.8% | |
| May 11, 2021 | ELAN Elanco Animal Health Inc | Hoover R David50 | See Remarks | Buy | 25,000 | $32.44 | $811,000.00 | +55.6% | -8.2% | -35.6% | |
| May 11, 2021 | TEVA Teva Pharmaceutical Industries Ltd | Stark David Matthew53 | Exec. VP Chief Legal Officer | Sell | 37,884 | $10.22 | $387,125.23 | -92.7% | -2.0% | -28.0% | |
| May 11, 2021 | TXMD Therapeuticsmd, Inc. | Donegan Michael C85 | CAO And VP Finance | Sell | 4,842 | $1.04 | $5,035.68 | -25.5% | -8.4% | -93.3% | |
| May 11, 2021 | TXMD Therapeuticsmd, Inc. | Walker Marlan D81 | General Counsel | Sell | 21,592 | $1.04 | $22,455.68 | -42.8% | -8.4% | -93.3% | |
| May 11, 2021 | TXMD Therapeuticsmd, Inc. | Borkowski Edward | EVP, Operations | Sell | 44,252 | $1.04 | $46,022.08 | -42.8% | -8.4% | -93.3% | |
| May 11, 2021 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | Secretary/ CEO Of Subsidiary | Sell | 44,252 | $1.04 | $46,022.08 | -2.5% | -8.4% | -93.3% | |
| May 11, 2021 | TXMD Therapeuticsmd, Inc. | Finizio Robert G | CEO | Sell | 67,697 | $1.04 | $70,404.88 | -0.4% | -8.4% | -93.3% | |
| May 10, 2021 | BMY Bristol Myers Squibb Co | Schmukler Louis S | EVP,Pres.,Glob.prod. &Supply | Sell | 15,000 | $65.25 | $978,750.00 | -31.9% | +4.9% | +21.7% | |
| May 10, 2021 | MRK Merck & Co., Inc. | Clyburn Frank | EVP &Pres ? Human Health | Sell | 19,324 | $78.32 | $1,513,440.22 | -17.0% | -2.8% | +16.4% | |
| May 10, 2021 | BCRX Biocryst Pharmaceuticals Inc | Abercrombie George B68 | Director | Sell | 7,000 | $12.70 | $88,900.00 | -70.0% | +47.9% | -27.9% | |
| May 10, 2021 | BMY Bristol Myers Squibb Co | Eid Joseph | SVP,Head Glob. Medical Affairs | Sell | 1,118 | $65.00 | $72,670.00 | -12.2% | +4.9% | +21.7% | |
| May 10, 2021 | COLL Collegium Pharmaceutical, Inc | Kuhlmann Shirley R.49 | EVP And General Counsel | Sell | 7,000 | $22.77 | $159,390.00 | -7.2% | -9.5% | -34.2% | |
| May 10, 2021 | UTHR United Therapeutics Corp | Patusky Christopher50 | Director | Sell | 100 | $190.52 | $19,052.00 | -7.7% | +9.4% | -5.7% | |
| May 7, 2021 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 1,011 | $35.03 | $35,415.33 | - | -1.7% | -9.6% | |
| May 7, 2021 | ALKS Alkermes Plc. | Landine Michael J | SVP, Corp Dev., Alkermes, Inc. | Sell | 19,477 | $22.10 | $430,521.56 | -8.2% | +27.2% | +25.6% | |
| May 6, 2021 | ALKS Alkermes Plc. | Pops Richard F57 | Director And CEO, Alkermes Plc | Sell | 100,000 | $21.79 | $2,179,410.00 | -11.2% | +27.1% | +25.5% | |
| May 6, 2021 | TAK Takeda Pharmaceutical Co Ltd | Takeda Pharmaceutical Co Ltd70 | 10% Owner | Sell | 7,138 | $35.14 | $250,803.06 | -0.3% | -0.7% | -8.2% | |
| May 6, 2021 | ESPR Esperion Therapeutics, Inc. | Biotech Target N V55 | 10% Owner | Buy | 230,000 | $20.21 | $4,648,482.00 | +2.9% | -32.7% | -73.5% | |
| May 5, 2021 | PFE Pfizer Inc | Damico Jennifer B.58 | SVP &Controller | Sell | 2,500 | $40.82 | $102,050.00 | -15.4% | +16.5% | +25.5% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.